FEB 21, 2018 09:00 AM PST

Application of a Novel Cell Proliferation Biomarker in Cancer Drug Development: Immunoassay of Thymidine Kinase 1 in In-Vitro and In-Vivo Studies of Hematological and Solid Malignancies

C.E. CREDITS: P.A.C.E. CE | Florida CE
  • Business Development Manager at AroCell AB
      Between 1994-2015 he worked at EKF Diagnostics in Wales (formerly Argutus Medical) where he introduced and promoted a wide range of novel kidney and liver tests, including important biomarkers that are now being evaluated by the IMI (Innovative Medicines Initiative) and FDA as qualified for use in toxicological testing. He developed strong relationships with hospitals, clinical research organizations and pharmaceutical companies, including AstraZeneca, Sanofi Aventis, Pfizer, Novartis, Merck, Glaxo Smith Kline and Johnson and Johnson.

      From 1975-1992 Martin Shaw filled many technical and marketing roles at Pharmacia Diagnostics (now Thermo-Fisher). He and his coworkers developed and introduced the first commercial tests for neonatal hypothyroidism, celiac disease, and a range of novel biomarkers to monitor allergy and inflammation.

      Bringing testing close to the patient is important and Martin brings this experience from being Marketing Manager at Magnasense Technologies, Finland, where he introduced and promoted a novel point-of-care test system based on magnetically labelled antibodies.

      Martin has published several peer-reviewed articles on biomarkers and presented at many scientific congresses, including being guest speaker at the FDA.


    There are many tumor biomarkers but, they mostly reflect tumor mass or past growth, when what is more important is to obtain an indication of future growth and therapy response.

    Proliferation biomarkers e.g. KI67, are mostly immunohistological biomarkers which limits their use. The ability to measure a proliferation biomarker in an easily available body fluid could reduce this problem and provide new opportunities for studying tumor growth and therapy response. 

    Thymidine Kinase 1 (TK1) has the potential to be such as biomarker. 

    This presentation will demonstrate how the immunoassay of TK1, using a unique monoclonal antibody directed against the TK 210 epitope (AroCell TK 210 ELISA) can provide new opportunities for the study of tumor growth, therapy response and in-vitro modelling of drug effects.

    Thymidine Kinase 1 (TK1) is a key enzyme in DNA synthesis and it is up-regulated in the S phase of cell growth. It is released into the extracellular medium and, eventually, the blood during cell turnover.

    TK1 enzyme activity has been used for many years as a biomarker for hematological malignancies but the complexity of the assay, plus the fact that much of serum TK1 is inactive has restricted its use, particularly for solid tumors. However, all TK1 forms express the TK 210 epitope.

    Show Resources
    Loading Comments...